Skip to main content
Top
Published in: Archives of Dermatological Research 9/2015

01-11-2015 | Original Paper

Pseudoceramide stimulates peroxisome proliferator-activated receptor-α expression in a murine model of atopic dermatitis: molecular basis underlying the anti-inflammatory effect and the preventive effect against steroid-induced barrier impairment

Authors: Sang Eun Lee, Min Kyung Jung, Seung Joon Oh, Se Kyoo Jeong, Seung Hun Lee

Published in: Archives of Dermatological Research | Issue 9/2015

Login to get access

Abstract

Topical pseudoceramides are successfully used in skin barrier repair therapy for atopic dermatitis (AD) and demonstrated to reduce the adverse effects of topical glucocorticoids (GC). However, the molecular mechanisms involved are not fully understood. We investigated whether PC-9S (myristoyl/palmitoyloxostearamide/arachamide MEA, Neopharm, Daejeon, Korea), one of the synthetic pseudoceramides, could stimulate peroxisome proliferator-activated receptor (PPAR)α expression in a hapten [oxazolone (oxa)]-induced AD murine model (oxa-AD mice) and subsequently improved permeability barrier, reduced inflammation, and increased antimicrobial peptides (AMPs) expression. Normal hairless mice and oxa-AD mice were topically treated twice daily with either PC-9S-containing physiologic lipid mixture (PLM), vehicle (PLM), or PPARα agonist for 4 days. Topical PC-9S significantly increased PPARα expression in mouse epidermis in vivo and in oxa-AD mice skin comparable with PPARα agonist. Topical PC-9S-containing PLM significantly reduced basal trans-epidermal water loss (TEWL), surface pH, and mast cell infiltrates and prevented the decline of AMPs expression in oxa-AD mice, which were abrogated by PPARα antagonist. Then, oxa-AD mice were treated with super-potent topical GC twice daily for 4 days with or without PC-9S co-applications. Co-treatment with PC-9S-containing PLM suppressed GC-induced increase in basal TEWL, epidermal thinning, reduced loricrin expression, and impaired barrier recovery and these effects were attenuated by PPARα antagonist. Collectively, our findings suggest that pseudoceramide PC-9S-induced stimulation of PPARα expression provides a new mechanism by which pseudoceramides show anti-inflammatory property, improve the permeability and antimicrobial barrier function, and prevent the negative effects of topical GC.
Literature
1.
go back to reference Aberg KM, Man MQ, Gallo RL, Ganz T, Crumrine D, Brown BE, Choi EH, Kim DK, Schroder JM, Feingold KR, Elias PM (2008) Co-regulation and interdependence of the mammalian epidermal permeability and antimicrobial barriers. J Invest Dermatol 128:917–925PubMedCentralCrossRefPubMed Aberg KM, Man MQ, Gallo RL, Ganz T, Crumrine D, Brown BE, Choi EH, Kim DK, Schroder JM, Feingold KR, Elias PM (2008) Co-regulation and interdependence of the mammalian epidermal permeability and antimicrobial barriers. J Invest Dermatol 128:917–925PubMedCentralCrossRefPubMed
2.
go back to reference Adachi Y, Hatano Y, Sakai T, Fujiwara S (2013) Expressions of peroxisome proliferator-activated receptors (PPARs) are directly influenced by permeability barrier abrogation and inflammatory cytokines and depressed PPARalpha modulates expressions of chemokines and epidermal differentiation-related molecules in keratinocytes. Exp Dermatol 22:606–608CrossRefPubMed Adachi Y, Hatano Y, Sakai T, Fujiwara S (2013) Expressions of peroxisome proliferator-activated receptors (PPARs) are directly influenced by permeability barrier abrogation and inflammatory cytokines and depressed PPARalpha modulates expressions of chemokines and epidermal differentiation-related molecules in keratinocytes. Exp Dermatol 22:606–608CrossRefPubMed
3.
go back to reference Chamlin SL, Kao J, Frieden IJ, Sheu MY, Fowler AJ, Fluhr JW, Williams ML, Elias PM (2002) Ceramide-dominant barrier repair lipids alleviate childhood atopic dermatitis: changes in barrier function provide a sensitive indicator of disease activity. J Am Acad Dermatol 47:198–208CrossRefPubMed Chamlin SL, Kao J, Frieden IJ, Sheu MY, Fowler AJ, Fluhr JW, Williams ML, Elias PM (2002) Ceramide-dominant barrier repair lipids alleviate childhood atopic dermatitis: changes in barrier function provide a sensitive indicator of disease activity. J Am Acad Dermatol 47:198–208CrossRefPubMed
4.
go back to reference Chiba T, Takeuchi S, Esaki H, Yamamura K, Kurihara Y, Moroi Y, Furue M (2012) Topical application of PPARalpha (but not beta/delta or gamma) suppresses atopic dermatitis in NC/Nga mice. Allergy 67:936–942CrossRefPubMed Chiba T, Takeuchi S, Esaki H, Yamamura K, Kurihara Y, Moroi Y, Furue M (2012) Topical application of PPARalpha (but not beta/delta or gamma) suppresses atopic dermatitis in NC/Nga mice. Allergy 67:936–942CrossRefPubMed
5.
go back to reference Dai X, Sayama K, Tohyama M, Shirakata Y, Hanakawa Y, Tokumaru S, Yang L, Hirakawa S, Hashimoto K (2010) PPARgamma mediates innate immunity by regulating the 1alpha,25-dihydroxyvitamin D3 induced hBD-3 and cathelicidin in human keratinocytes. J Dermatol Sci 60:179–186CrossRefPubMed Dai X, Sayama K, Tohyama M, Shirakata Y, Hanakawa Y, Tokumaru S, Yang L, Hirakawa S, Hashimoto K (2010) PPARgamma mediates innate immunity by regulating the 1alpha,25-dihydroxyvitamin D3 induced hBD-3 and cathelicidin in human keratinocytes. J Dermatol Sci 60:179–186CrossRefPubMed
6.
go back to reference de Koning HD, Kamsteeg M, Rodijk-Olthuis D, van Vlijmen-Willems IM, van Erp PE, Schalkwijk J, Zeeuwen PL (2011) Epidermal expression of host response genes upon skin barrier disruption in normal skin and uninvolved skin of psoriasis and atopic dermatitis patients. J Invest Dermatol 131:263–266CrossRefPubMed de Koning HD, Kamsteeg M, Rodijk-Olthuis D, van Vlijmen-Willems IM, van Erp PE, Schalkwijk J, Zeeuwen PL (2011) Epidermal expression of host response genes upon skin barrier disruption in normal skin and uninvolved skin of psoriasis and atopic dermatitis patients. J Invest Dermatol 131:263–266CrossRefPubMed
7.
go back to reference Demerjian M, Choi EH, Man MQ, Chang S, Elias PM, Feingold KR (2009) Activators of PPARs and LXR decrease the adverse effects of exogenous glucocorticoids on the epidermis. Exp Dermatol 18:643–649PubMedCentralCrossRefPubMed Demerjian M, Choi EH, Man MQ, Chang S, Elias PM, Feingold KR (2009) Activators of PPARs and LXR decrease the adverse effects of exogenous glucocorticoids on the epidermis. Exp Dermatol 18:643–649PubMedCentralCrossRefPubMed
8.
go back to reference Draelos ZD (2008) The effect of ceramide-containing skin care products on eczema resolution duration. Cutis 81:87–91PubMed Draelos ZD (2008) The effect of ceramide-containing skin care products on eczema resolution duration. Cutis 81:87–91PubMed
9.
go back to reference Geilen CC, Wieder T, Orfanos CE (1997) Ceramide signalling: regulatory role in cell proliferation, differentiation and apoptosis in human epidermis. Arch Dermatol Res 289:559–566CrossRefPubMed Geilen CC, Wieder T, Orfanos CE (1997) Ceramide signalling: regulatory role in cell proliferation, differentiation and apoptosis in human epidermis. Arch Dermatol Res 289:559–566CrossRefPubMed
10.
go back to reference Hatano Y, Elias PM, Crumrine D, Feingold KR, Katagiri K, Fujiwara S (2011) Efficacy of combined peroxisome proliferator-activated receptor-alpha ligand and glucocorticoid therapy in a murine model of atopic dermatitis. J Invest Dermatol 131:1845–18452PubMedCentralCrossRefPubMed Hatano Y, Elias PM, Crumrine D, Feingold KR, Katagiri K, Fujiwara S (2011) Efficacy of combined peroxisome proliferator-activated receptor-alpha ligand and glucocorticoid therapy in a murine model of atopic dermatitis. J Invest Dermatol 131:1845–18452PubMedCentralCrossRefPubMed
11.
go back to reference Hatano Y, Man MQ, Uchida Y, Crumrine D, Mauro TM, Feingold KR, Elias PM, Holleran WM (2010) Murine atopic dermatitis responds to peroxisome proliferator-activated receptors alpha and beta/delta (but not gamma) and liver X receptor activators. J Allergy Clin Immunol 125:160–169PubMedCentralCrossRefPubMed Hatano Y, Man MQ, Uchida Y, Crumrine D, Mauro TM, Feingold KR, Elias PM, Holleran WM (2010) Murine atopic dermatitis responds to peroxisome proliferator-activated receptors alpha and beta/delta (but not gamma) and liver X receptor activators. J Allergy Clin Immunol 125:160–169PubMedCentralCrossRefPubMed
12.
go back to reference Imokawa G, Abe A, Jin K, Higaki Y, Kawashima M, Hidano A (1991) Decreased level of ceramides in stratum corneum of atopic dermatitis: an etiologic factor in atopic dry skin? J Invest Dermatol 96:523–526CrossRefPubMed Imokawa G, Abe A, Jin K, Higaki Y, Kawashima M, Hidano A (1991) Decreased level of ceramides in stratum corneum of atopic dermatitis: an etiologic factor in atopic dry skin? J Invest Dermatol 96:523–526CrossRefPubMed
13.
go back to reference Imokawa G, Akasaki S, Kawamata A, Yano S, Takaishi N (1989) Water-retaining function in the stratum-corneum and its recovery properties by synthetic pseudoceramides. J Soc Cosmet Chem 40:273–285 Imokawa G, Akasaki S, Kawamata A, Yano S, Takaishi N (1989) Water-retaining function in the stratum-corneum and its recovery properties by synthetic pseudoceramides. J Soc Cosmet Chem 40:273–285
14.
go back to reference Imokawa G, Yada Y, Higuchi K, Okuda M, Ohashi Y, Kawamata A (1994) Pseudo-acylceramide with linoleic acid produces selective recovery of diminished cutaneous barrier function in essential fatty acid-deficient rats and has an inhibitory effect on epidermal hyperplasia. J Clin Invest 94:89–96PubMedCentralCrossRefPubMed Imokawa G, Yada Y, Higuchi K, Okuda M, Ohashi Y, Kawamata A (1994) Pseudo-acylceramide with linoleic acid produces selective recovery of diminished cutaneous barrier function in essential fatty acid-deficient rats and has an inhibitory effect on epidermal hyperplasia. J Clin Invest 94:89–96PubMedCentralCrossRefPubMed
15.
go back to reference Janssens M, van Smeden J, Gooris GS, Bras W, Portale G, Caspers PJ, Vreeken RJ, Kezic S, Lavrijsen AP, Bouwstra JA (2011) Lamellar lipid organization and ceramide composition in the stratum corneum of patients with atopic eczema. J Invest Dermatol 131:2136–2138CrossRefPubMed Janssens M, van Smeden J, Gooris GS, Bras W, Portale G, Caspers PJ, Vreeken RJ, Kezic S, Lavrijsen AP, Bouwstra JA (2011) Lamellar lipid organization and ceramide composition in the stratum corneum of patients with atopic eczema. J Invest Dermatol 131:2136–2138CrossRefPubMed
16.
go back to reference Jiang YJ, Uchida Y, Lu B, Kim P, Mao C, Akiyama M, Elias PM, Holleran WM, Grunfeld C, Feingold KR (2009) Ceramide stimulates ABCA12 expression via peroxisome proliferator-activated receptor delta in human keratinocytes. J Biol Chem 284:18942–18952PubMedCentralCrossRefPubMed Jiang YJ, Uchida Y, Lu B, Kim P, Mao C, Akiyama M, Elias PM, Holleran WM, Grunfeld C, Feingold KR (2009) Ceramide stimulates ABCA12 expression via peroxisome proliferator-activated receptor delta in human keratinocytes. J Biol Chem 284:18942–18952PubMedCentralCrossRefPubMed
17.
go back to reference Kang JS, Lee CW, Lee K, Han MH, Lee H, Youm JK, Jeong SK, Park BD, Han SB, Han G, Park SK, Kim HM (2008) Inhibition of skin inflammation and atopic dermatitis by topical application of a novel ceramide derivative, K112PC-5, in mice. Arch Pharm Res 31:1004–1009CrossRefPubMed Kang JS, Lee CW, Lee K, Han MH, Lee H, Youm JK, Jeong SK, Park BD, Han SB, Han G, Park SK, Kim HM (2008) Inhibition of skin inflammation and atopic dermatitis by topical application of a novel ceramide derivative, K112PC-5, in mice. Arch Pharm Res 31:1004–1009CrossRefPubMed
18.
go back to reference Kang JS, Yoon WK, Youm JK, Jeong SK, Park BD, Han MH, Lee H, Moon EY, Han SB, Lee CW, Lee K, Park SK, Yang KH, Kim HM (2008) Inhibition of atopic dermatitis-like skin lesions by topical application of a novel ceramide derivative, K6PC-9p, in NC/Nga mice. Exp Dermatol 17:958–964CrossRefPubMed Kang JS, Yoon WK, Youm JK, Jeong SK, Park BD, Han MH, Lee H, Moon EY, Han SB, Lee CW, Lee K, Park SK, Yang KH, Kim HM (2008) Inhibition of atopic dermatitis-like skin lesions by topical application of a novel ceramide derivative, K6PC-9p, in NC/Nga mice. Exp Dermatol 17:958–964CrossRefPubMed
19.
go back to reference Kim HJ, Park HJ, Yun JN, Jeong SK, Ahn SK, Lee SH (2011) Pseudoceramide-containing physiological lipid mixture reduces adverse effects of topical steroids. Allergy Asthma Immunol Res 3:96–102PubMedCentralCrossRefPubMed Kim HJ, Park HJ, Yun JN, Jeong SK, Ahn SK, Lee SH (2011) Pseudoceramide-containing physiological lipid mixture reduces adverse effects of topical steroids. Allergy Asthma Immunol Res 3:96–102PubMedCentralCrossRefPubMed
20.
go back to reference Lee HK, Nam GW, Kim SH, Lee SH (2006) Phytocomponents of triterpenoids, oleanolic acid and ursolic acid, regulated differently the processing of epidermal keratinocytes via PPAR-alpha pathway. Exp Dermatol 15:66–73CrossRefPubMed Lee HK, Nam GW, Kim SH, Lee SH (2006) Phytocomponents of triterpenoids, oleanolic acid and ursolic acid, regulated differently the processing of epidermal keratinocytes via PPAR-alpha pathway. Exp Dermatol 15:66–73CrossRefPubMed
21.
go back to reference Lee YB, Park HJ, Kwon MJ, Jeong SK, Cho SH (2011) Beneficial effects of pseudoceramide-containing physiologic lipid mixture as a vehicle for topical steroids. Eur J Dermatol 21:710–716PubMed Lee YB, Park HJ, Kwon MJ, Jeong SK, Cho SH (2011) Beneficial effects of pseudoceramide-containing physiologic lipid mixture as a vehicle for topical steroids. Eur J Dermatol 21:710–716PubMed
22.
go back to reference Man MQ, Choi EH, Schmuth M, Crumrine D, Uchida Y, Elias PM, Holleran WM, Feingold KR (2006) Basis for improved permeability barrier homeostasis induced by PPAR and LXR activators: liposensors stimulate lipid synthesis, lamellar body secretion, and post-secretory lipid processing. J Invest Dermatol 126:386–392CrossRefPubMed Man MQ, Choi EH, Schmuth M, Crumrine D, Uchida Y, Elias PM, Holleran WM, Feingold KR (2006) Basis for improved permeability barrier homeostasis induced by PPAR and LXR activators: liposensors stimulate lipid synthesis, lamellar body secretion, and post-secretory lipid processing. J Invest Dermatol 126:386–392CrossRefPubMed
23.
go back to reference Man MQ, Hatano Y, Lee SH, Man M, Chang S, Feingold KR, Leung DY, Holleran W, Uchida Y, Elias PM (2008) Characterization of a hapten-induced, murine model with multiple features of atopic dermatitis: structural, immunologic, and biochemical changes following single versus multiple oxazolone challenges. J Invest Dermatol 128:79–86PubMedCentralCrossRefPubMed Man MQ, Hatano Y, Lee SH, Man M, Chang S, Feingold KR, Leung DY, Holleran W, Uchida Y, Elias PM (2008) Characterization of a hapten-induced, murine model with multiple features of atopic dermatitis: structural, immunologic, and biochemical changes following single versus multiple oxazolone challenges. J Invest Dermatol 128:79–86PubMedCentralCrossRefPubMed
24.
go back to reference Moraes LA, Piqueras L, Bishop-Bailey D (2006) Peroxisome proliferator-activated receptors and inflammation. Pharmacol Ther 110:371–385CrossRefPubMed Moraes LA, Piqueras L, Bishop-Bailey D (2006) Peroxisome proliferator-activated receptors and inflammation. Pharmacol Ther 110:371–385CrossRefPubMed
25.
go back to reference Nomura I, Goleva E, Howell MD, Hamid QA, Ong PY, Hall CF, Darst MA, Gao B, Boguniewicz M, Travers JB, Leung DY (2003) Cytokine milieu of atopic dermatitis, as compared to psoriasis, skin prevents induction of innate immune response genes. J Immunol 171:3262–3269CrossRefPubMed Nomura I, Goleva E, Howell MD, Hamid QA, Ong PY, Hall CF, Darst MA, Gao B, Boguniewicz M, Travers JB, Leung DY (2003) Cytokine milieu of atopic dermatitis, as compared to psoriasis, skin prevents induction of innate immune response genes. J Immunol 171:3262–3269CrossRefPubMed
26.
go back to reference Ong PY, Ohtake T, Brandt C, Strickland I, Boguniewicz M, Ganz T, Gallo RL, Leung DY (2002) Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med 347:1151–1160CrossRefPubMed Ong PY, Ohtake T, Brandt C, Strickland I, Boguniewicz M, Ganz T, Gallo RL, Leung DY (2002) Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med 347:1151–1160CrossRefPubMed
27.
go back to reference Peyrin-Biroulet L, Beisner J, Wang G, Nuding S, Oommen ST, Kelly D, Parmentier-Decrucq E, Dessein R, Merour E, Chavatte P, Grandjean T, Bressenot A, Desreumaux P, Colombel JF, Desvergne B, Stange EF, Wehkamp J, Chamaillard M (2010) Peroxisome proliferator-activated receptor gamma activation is required for maintenance of innate antimicrobial immunity in the colon. Proc Natl Acad Sci USA 107:8772–8777PubMedCentralCrossRefPubMed Peyrin-Biroulet L, Beisner J, Wang G, Nuding S, Oommen ST, Kelly D, Parmentier-Decrucq E, Dessein R, Merour E, Chavatte P, Grandjean T, Bressenot A, Desreumaux P, Colombel JF, Desvergne B, Stange EF, Wehkamp J, Chamaillard M (2010) Peroxisome proliferator-activated receptor gamma activation is required for maintenance of innate antimicrobial immunity in the colon. Proc Natl Acad Sci USA 107:8772–8777PubMedCentralCrossRefPubMed
28.
go back to reference Plager DA, Leontovich AA, Henke SA, Davis MD, McEvoy MT, Sciallis GF 2nd, Pittelkow MR (2007) Early cutaneous gene transcription changes in adult atopic dermatitis and potential clinical implications. Exp Dermatol 16:28–36CrossRefPubMed Plager DA, Leontovich AA, Henke SA, Davis MD, McEvoy MT, Sciallis GF 2nd, Pittelkow MR (2007) Early cutaneous gene transcription changes in adult atopic dermatitis and potential clinical implications. Exp Dermatol 16:28–36CrossRefPubMed
29.
go back to reference Sheu MY, Fowler AJ, Kao J, Schmuth M, Schoonjans K, Auwerx J, Fluhr JW, Man MQ, Elias PM, Feingold KR (2002) Topical peroxisome proliferator activated receptor-alpha activators reduce inflammation in irritant and allergic contact dermatitis models. J Invest Dermatol 118:94–101CrossRefPubMed Sheu MY, Fowler AJ, Kao J, Schmuth M, Schoonjans K, Auwerx J, Fluhr JW, Man MQ, Elias PM, Feingold KR (2002) Topical peroxisome proliferator activated receptor-alpha activators reduce inflammation in irritant and allergic contact dermatitis models. J Invest Dermatol 118:94–101CrossRefPubMed
30.
go back to reference Staumont-Salle D, Abboud G, Brenuchon C, Kanda A, Roumier T, Lavogiez C, Fleury S, Remy P, Papin JP, Bertrand-Michel J, Terce F, Staels B, Delaporte E, Capron M, Dombrowicz D (2008) Peroxisome proliferator-activated receptor alpha regulates skin inflammation and humoral response in atopic dermatitis. J Allergy Clin Immunol 121:962–968CrossRefPubMed Staumont-Salle D, Abboud G, Brenuchon C, Kanda A, Roumier T, Lavogiez C, Fleury S, Remy P, Papin JP, Bertrand-Michel J, Terce F, Staels B, Delaporte E, Capron M, Dombrowicz D (2008) Peroxisome proliferator-activated receptor alpha regulates skin inflammation and humoral response in atopic dermatitis. J Allergy Clin Immunol 121:962–968CrossRefPubMed
31.
go back to reference Tsuji K, Satoh S, Mitsutake S, Murakami I, Park JJ, Li Q, Chang YT, Chung SK, Igarashi Y (2009) Evaluation of synthetic sphingolipid analogs as ligands for peroxisome proliferator-activated receptors. Bioorg Med Chem Lett 19:1643–1646CrossRefPubMed Tsuji K, Satoh S, Mitsutake S, Murakami I, Park JJ, Li Q, Chang YT, Chung SK, Igarashi Y (2009) Evaluation of synthetic sphingolipid analogs as ligands for peroxisome proliferator-activated receptors. Bioorg Med Chem Lett 19:1643–1646CrossRefPubMed
32.
go back to reference Wiren K, Nohlgard C, Nyberg F, Holm L, Svensson M, Johannesson A, Wallberg P, Berne B, Edlund F, Loden M (2009) Treatment with a barrier-strengthening moisturizing cream delays relapse of atopic dermatitis: a prospective and randomized controlled clinical trial. J Eur Acad Dermatol Venereol 23:1267–1272CrossRefPubMed Wiren K, Nohlgard C, Nyberg F, Holm L, Svensson M, Johannesson A, Wallberg P, Berne B, Edlund F, Loden M (2009) Treatment with a barrier-strengthening moisturizing cream delays relapse of atopic dermatitis: a prospective and randomized controlled clinical trial. J Eur Acad Dermatol Venereol 23:1267–1272CrossRefPubMed
33.
go back to reference Yoon NY, Jung MY, Kim DH, Lee HJ, Choi EH (2015) Topical glucocorticoid or pimecrolimus treatment suppresses thymic stromal lymphopoietin-related allergic inflammatory mechanism in an oxazolone-induced atopic dermatitis murine model. Arch Dermatol Res. doi:10.1007/s00403-015-1558-y Yoon NY, Jung MY, Kim DH, Lee HJ, Choi EH (2015) Topical glucocorticoid or pimecrolimus treatment suppresses thymic stromal lymphopoietin-related allergic inflammatory mechanism in an oxazolone-induced atopic dermatitis murine model. Arch Dermatol Res. doi:10.​1007/​s00403-015-1558-y
Metadata
Title
Pseudoceramide stimulates peroxisome proliferator-activated receptor-α expression in a murine model of atopic dermatitis: molecular basis underlying the anti-inflammatory effect and the preventive effect against steroid-induced barrier impairment
Authors
Sang Eun Lee
Min Kyung Jung
Seung Joon Oh
Se Kyoo Jeong
Seung Hun Lee
Publication date
01-11-2015
Publisher
Springer Berlin Heidelberg
Published in
Archives of Dermatological Research / Issue 9/2015
Print ISSN: 0340-3696
Electronic ISSN: 1432-069X
DOI
https://doi.org/10.1007/s00403-015-1584-9

Other articles of this Issue 9/2015

Archives of Dermatological Research 9/2015 Go to the issue